AI Summary
✦ ClarthaValuation Metrics
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
Historical valuation metrics are unavailable for this ticker right now.
Peers & Comparison
Sector: Health Care · Theme: Biotechnology
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
HESTER BIOSCIENCES LTD HESTERBIOBiotechnology | -8.2% | 41.6% | 15.5x Undervalued | -80% vs avg | +30.7% |
ONESOURCE SPECL PHARMA L ONESOURCEBiotechnology | +37.2% | -3.1% | — | — | -16.9% |
BIOGEN PHARMACHEM INDUSTRIES LTD BIOGEN PHARMACHEM INDUSTRIES LTDBiotechnology | — | — | — | — | — |
BIOCON LIMITED. BIOCONBiotechnology | +10.0% | 2.9% | 123.9x Premium | +56% vs avg | +20.1% |
ANTHEM BIOSCIENCES LTD ANTHEMBiotechnology | -22.6% | 28.7% | 82.8x Fair | +4% vs avg | +19.9% |
SAI LIFE SCIENCES LIMITED SAILIFEBiotechnology | +11.7% | 16.1% | 85.1x Fair | +7% vs avg | +60.0% |
ACUTAAS CHEMICALS LIMITED ACUTAASBiotechnology | +59.1% | 26.4% | 89.9x Fair | +13% vs avg | +149.2% |
SHEEL SHEELBiotechnology | — | — | — | — | — |
Comparable-scale peer data is limited — showing nearest stored business/industry peers instead of an empty comparison.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹111 CrMar 2026Latest net profit
₹-0.18 CrMar 2026Latest EPS
₹-0.03Mar 2026Net margin
0.3%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 75.02 | 89.41 | 94.59 | 95.23 | 80.37 | 56.88 | 76.64 | 108.43 | 67.90 | 112.25 | 90.81 | 99.31 | 111.12 |
| Expenses + | 71.59 | 82.60 | 84.63 | 88.59 | 89.61 | 67.37 | 69.90 | 93.04 | 86.47 | 115.27 | 104.51 | 100.69 | 110.82 |
| Operating Profit | 3.43 | 6.81 | 9.96 | 6.64 | -9.24 | -10.49 | 6.74 | 15.39 | -18.57 | -3.02 | -13.70 | -1.38 | 0.30 |
| OPM % | 4.57% | 7.62% | 10.53% | 6.97% | -11.50% | -18.44% | 8.79% | 14.19% | -27.35% | -2.69% | -15.09% | -1.39% | 0.27% |
| Other Income + | 10.27 | 3.34 | 2.13 | 3.05 | 16.39 | 3.80 | 3.41 | 3.32 | 6.09 | 4.95 | 3.61 | 3.84 | 5.60 |
| Interest | 2.70 | 3.46 | 3.55 | 3.41 | 3.36 | 3.21 | 3.76 | 3.85 | 4.64 | 6.00 | 5.93 | 7.04 | 6.33 |
| Depreciation | 5.90 | 5.40 | 5.34 | 5.21 | 5.14 | 5.08 | 5.09 | 5.21 | 4.91 | 4.77 | 4.91 | 4.89 | 4.18 |
| Profit before tax | 5.10 | 1.29 | 3.20 | 1.07 | -1.35 | -14.98 | 1.30 | 9.65 | -22.03 | -8.84 | -20.93 | -9.47 | -4.61 |
| Tax % | 486.08% | -0.00% | -0.00% | 59.81% | 1.48% | -8.01% | 0.77% | -0.00% | -43.76% | -24.21% | -25.27% | -22.28% | -96.10% |
| Net Profit + | -19.69 | 1.29 | 3.20 | 0.43 | -1.37 | -13.78 | 1.29 | 9.65 | -12.39 | -6.70 | -15.64 | -7.36 | -0.18 |
| EPS in Rs | -3.21 | 0.21 | 0.52 | 0.07 | -0.22 | -2.25 | 0.21 | 1.57 | -2.02 | -1.09 | -2.55 | -1.20 | -0.03 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Board Meeting Intimation for Inter-Alia, Approval Of Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter Ended June 30, 2026
Details Of Shares Dematerialized During July 2026 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 ('SEBI LODR Regulations')